Improvement of high-density lipoprotein atheroprotective properties in patients with systemic lupus erythematosus after belimumab treatment

被引:4
|
作者
Dedemadi, Anastasia-Georgia [1 ,2 ]
Gkolfinopoulou, Christina [1 ]
Nikoleri, Dimitra [3 ,4 ]
Nikoloudaki, Myrto [3 ]
Ruhanen, Hanna [5 ,6 ,7 ]
Holopainen, Minna [5 ,6 ,7 ]
Kakela, Reijo [6 ,7 ]
Christopoulou, Georgia [8 ]
Bournazos, Stavros [8 ]
Constantoulakis, Pantelis [8 ]
Sidiropoulos, Prodromos [3 ,4 ]
Bertsias, George [3 ,4 ]
Chroni, Angeliki [1 ]
机构
[1] Natl Ctr Sci Res Demokritos, Inst Biosci & Applicat, Athens 15341, Greece
[2] Natl & Kapodistrian Univ Athens, Dept Chem, Athens, Greece
[3] Univ Crete, Med Sch, Lab Rheumatol Autoimmun & Inflammat, Iraklion, Greece
[4] FORTH, Inst Mol Biol & Biotechnol, Iraklion, Greece
[5] Univ Helsinki, Helsinki Inst Life Sci, Lipid Unit, HiLIPID, Helsinki, Finland
[6] Bioctr Finland, Helsinki, Finland
[7] Univ Helsinki, Fac Biol & Environm Sci, Mol & Integrat Biosci Res Program, Helsinki, Finland
[8] Genotypos Sci Labs, Athens, Greece
关键词
systemic lupus erythematosus; biologicals; high-density lipoprotein; atheroprotection; lipidomic profile; CHOLESTEROL EFFLUX CAPACITY; ATHEROSCLEROSIS; FUNCTIONALITY;
D O I
10.1093/rheumatology/keae192
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Chronic inflammatory diseases, like Systemic Lupus Erythematosus (SLE), carry an increased risk for atherosclerosis and cardiovascular events, accompanied by impairment of atheroprotective properties of high-density lipoprotein (HDL). In SLE, serum B cell-activating factor (BAFF), a cytokine implicated in disease progression, has been correlated with subclinical atherosclerosis. We investigated the impact of treatment with belimumab -an anti-BAFF monoclonal antibody- on HDL atheroprotective properties and composition in SLE patients.Methods Serum samples were collected from 35 SLE patients with active disease despite conventional therapy, before and after 6-month add-on treatment with belimumab, and 26 matched healthy individuals. We measured cholesterol efflux and antioxidant capacities, paraoxonase-1 (PON1) activity, serum amyloid A1 (SAA1), myeloperoxidase (MPO) and lipid peroxidation product levels of HDL. LC-MS/MS was performed to analyse the HDL lipidome.Results Following treatment with belimumab, cholesterol efflux and antioxidant capacities of HDL were significantly increased in SLE patients and restored to levels of control subjects. HDL-associated PON1 activity was also increased, whereas lipid peroxidation products were decreased following treatment. HDL cholesterol efflux and antioxidant capacities correlated negatively with the disease activity. Changes were noted in the HDL lipidome of SLE patients following belimumab treatment, as well as between SLE patients and healthy individuals, and specific changes in lipid species correlated with functional parameters of HDL.Conclusions HDL of SLE patients with active disease displays impaired atheroprotective properties accompanied by distinct lipidomic signatures compared with controls. Belimumab treatment may improve the HDL atheroprotective properties and modify the HDL lipidomic signature in SLE patients, thus potentially mitigating atherosclerosis development. Graphical Abstract
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Anti-atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus
    Batuca, J. R.
    Ames, P. R. J.
    Amaral, M.
    Favas, C.
    Isenberg, D. A.
    Alves, J. Delgado
    RHEUMATOLOGY, 2009, 48 (01) : 26 - 31
  • [22] EFFICACY OF BELIMUMAB TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS AT OUR HOSPITAL
    Mizusaki, M.
    Wakiya, R.
    Nakashima, S.
    Shimada, H.
    Sugihara, K.
    Kato, M.
    Miyagi, T.
    Ushio, Y.
    Mino, R.
    Chujo, K.
    Kameda, T.
    Dobashi, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1347 - 1347
  • [23] Belimumab: First targeted biological treatment for systemic lupus erythematosus
    Dubey, Ashok K.
    Handu, Shailendra S.
    Dubey, Suparna
    Sharma, Prashant
    Sharma, K. K.
    Ahmed, Qazi M.
    JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS, 2011, 2 (04) : 317 - 319
  • [24] Efficacy of a sequential treatment by belimumab in monogenic systemic lupus erythematosus
    Akbar, Lujayn
    Alsagheir, Razan
    Al-Mayouf, Sulaiman M.
    EUROPEAN JOURNAL OF RHEUMATOLOGY, 2020, 7 (04) : 184 - 189
  • [25] Systemic lupus erythematosus exacerbation following cessation of belimumab treatment
    Furer, V.
    Zisman, D.
    Pokroy-Shapira, E.
    Molad, Y.
    Elkayam, O.
    Paran, D.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2016, 45 (02) : 103 - 106
  • [26] Can the dose of belimumab be reduced in patients with systemic lupus erythematosus?
    Rua-Figueroa, Inigo
    Altabas-Gonzalez, Irene
    Mourino, Coral
    Roberts, Karen
    Hernandez-Martin, Andrea
    Casafont-Sole, Ivette
    Font-Urgelles, Judit
    Roman-Ivorra, Jose A.
    Navarro, Marta de la Rubia
    Galindo-Izquierdo, Maria
    Salman-Monte, Tarek C.
    Narvaez, Javier
    Vidal-Montal, Paola
    Garcia-Villanueva, Maria Jesus
    Garrote-Corral, Sandra
    Blazquez-Canamero, Maria Angeles
    Fernandez-Cid, Carlos Marras
    Piqueras-Garcia, Maria
    Martinez-Barrio, Julia
    Sanchez-Lucas, Marina
    Cortes-Hernandez, Josefina
    Penzo, Eleonora
    Calvo-Alen, Jaime
    de Dios, Juan Ramon
    Alvarez-Rodriguez, Belen
    Vasques-Rocha, Margarida
    Tomero, Eva
    Menor-Almagro, Raul
    Gandia, Myriam
    Gomez-Puerta, Jose A.
    Frade-Sosa, Beatriz
    Ramos-Giraldez, Consuelo
    Trapero-Perez, Carmen
    Diez, Elvira
    Moriano, Clara
    Munoz-Jimenez, Alejandro
    Pego-Reigosa, Jose Maria
    RHEUMATOLOGY, 2024,
  • [27] SPANISH NATIONAL REGISTRY OF BELIMUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
    Laino, M.
    Enguita, M.
    Castaneda, S.
    Loricera, J.
    Moriano, C.
    Lasa, C.
    Calvo-Rio, V.
    Narvaez, J.
    Navarro Palomo, P.
    Casafont-Sole, I.
    Font, J.
    Gallego, A.
    Carrion Barbera, I.
    Quiroga Colino, P.
    Garcia-Aparicio, A.
    Belzunegui Otano, J. M.
    Lopez, M.
    Jimenez de Aberasturi, J. R. De Dios
    Hernandez, S.
    Heredia, S.
    Farina, A.
    Navarro Blasco, F. J.
    Ortega Castro, R.
    Del Olmo Perez, L.
    Labrador-Sanchez, E.
    Pinillos, V.
    Ortega de la O, M. C.
    Castro, P.
    Blanco, J. M.
    Paulino Huertas, M.
    Matias de la Mano, M. A.
    Peralta-Gines, C.
    Garcia-Cirera, S.
    Camins, J.
    Urruticoechea-Arana, A.
    Medina Malone, M.
    Cossio Jimenez, P. J.
    Perez-Pampin, E.
    Varas, B.
    Vazquez, C.
    Vegas-Revenga, N.
    Rusinovich, O.
    Giner, E.
    Lamua-Riazuelo, J. R.
    Aldasoro, V.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 899 - 901
  • [28] Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus
    Aldasoro, Vicente
    Laino, Maria
    Enguita, Monica
    Castaneda, Santos
    Loricera, Javier
    Lasa-Teja, Carmen
    Moriano, Clara
    Rio, Vanesa Calvo
    Casafont-Sole, Ivette
    Font Urgelles, Judit
    Quiroga-Colina, Patricia
    Hernandez, Samuel
    Heredia, Sergi
    Garcia-Aparicio, A.
    Belzunegui Otano, Joaquin Maria
    Farina, Aaron
    Navarro Blasco, Francisco Javier
    Fanlo Mateo, Patricia
    Gallego, Adela
    Blanco Madrigal, Juan M.
    Angeles Matias, Maria
    Peralta, Cilia
    Camins-Fabregas, Jordi
    Paulino, Marcos
    Urruticoechea, Ana
    Cossio Jimenez, Piter Jose
    Medina Malone, Miguel
    Perez Pampin, Eva
    Ortega-Castro, Rafaela
    Varas de Dios, Blanca
    Lamua Riazuelo, Jose Ramon
    Jose Giner, Emilio
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 692 - 695
  • [29] Efficacy and safety data of belimumab in patients with systemic lupus erythematosus
    Shakoory, Bita
    Clatham, Winn
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2011, 3 (03) : 159 - 164
  • [30] COMBINATION THERAPY WITH RITUXIMAB AND BELIMUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
    Mesnyankina, A.
    Aseeva, E.
    Nikishina, N.
    Torgashina, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1168 - 1168